Go Pro
NASDAQ:VIRI

Virios Therapeutics (VIRI) Stock Price, News & Analysis

Virios Therapeutics logo
$1.46 +0.03 (+2.10%)
As of 10/2/2026

About Virios Therapeutics Stock (NASDAQ:VIRI)

Advanced

Key Stats

Today's Range
$1.43
▼
$1.56
50-Day Range
$1.35
▼
$2.68
52-Week Range
$0.13
▼
$1.04
Volume
71,089 shs
Average Volume
1.05 million shs
Market Capitalization
$28.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Virios Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antiviral therapies for diseases that may be associated with abnormal activation or reactivation of herpes-family viruses. The company’s research is based on the premise that viral activity can contribute to chronic inflammatory and pain-related conditions.

Virios’ lead investigational product is IMC-1, a fixed-dose combination of famciclovir and celecoxib being developed for the treatment of fibromyalgia. The company has evaluated IMC-1 in clinical studies and has also explored additional applications for its antiviral and anti-inflammatory development approach. These products remain investigational and have not been approved for commercial use.

Virios Therapeutics was established in 2018 and is based in Alpharetta, Georgia. Its activities have primarily centered on drug discovery, clinical development and partnerships related to chronic pain and other conditions in which viral reactivation may play a role.

AI Generated. May Contain Errors.

Receive VIRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VIRI Stock News Headlines

Virios Therapeutics (NASDAQ:VIRI) Trading Down 1.7% - Here's Why
Dogwood Therapeutics Inc (DWTX)
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
Dogwood prices 578,950 shares at $8.26 in registered direct offering
Dogwood announces conversion of existing $19.5M in debt to equity
DWTX Stock trading resumes
Dogwood Therapeutics, Inc. (DWTX)
DWTX Stock trading halted, volatility trading pause
See More Headlines

VIRI Stock Analysis - Frequently Asked Questions

Virios Therapeutics' stock was trading at $4.16 at the beginning of 2026. Since then, VIRI stock has decreased by 64.9% and is now trading at $1.46.

Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.02.

Virios Therapeutics (VIRI) raised $30 million in an IPO on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Virios Therapeutics investors own include Meta Platforms (META), AMC Entertainment (AMC), SNDL (SNDL), CISO Global (CISO), Canoo (GOEV), Organigram Global (OGI).

Company Calendar

Last Earnings
8/08/2024
Today
10/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VIRI
CIK
1818844
Fax
N/A
Employees
5
Year Founded
2012

Profitability

EPS (Trailing Twelve Months)
($0.27)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.30 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-130.33%
Return on Assets
-115.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.27
Quick Ratio
7.27

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.20 per share
Price / Book
7.30

Miscellaneous

Outstanding Shares
19,258,000
Free Float
16,909,000
Market Cap
$28.12 million
Optionable
No Data
Beta
1.58

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:VIRI) was last updated on 10/3/2026 by MarketBeat.com Staff.
From Our Partners